From Wikipedia, the free encyclopedia
|Mol. mass||145,255 Daltons|
|(what is this?)|
This drug was developed by Kyowa Hakko Kogyo Co., Ltd.
- Statement On A Nonproprietary Name Adopted By The USAN Council - Ecromeximab, American Medical Association.
- ClinicalTrials.gov NCT00679289 Phase II Study of KW2871 Combined With High Dose Interferon-alpha2b in Patients With Metastatic Cutaneous Melanoma
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|